TriSalus Life Sciences, Inc.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ D
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
(in thousands, except share data)
| Preferred stock · Common stock · Additionalpaid-incapital · Accumulateddeficit · Total | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | |||||||||||||||||
| At December 31, 2022 | — | $— | 347,926 | $— | $10,028 | $(187,160) | $(177,132) | ||||||||||
| Exercise of options | — | — | 247,612 | — | 180 | — | 180 | ||||||||||
| Stock-based compensation | — | — | — | — | 1,402 | — | 1,402 | ||||||||||
| Deemed dividend | — | — | — | — | 2,981 | (2,981) | — | ||||||||||
| Impact of Business Combination | |||||||||||||||||
| Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination | — | — | 21,500,867 | 2 | 204,234 | — | 204,236 | ||||||||||
| Assumption of warrants to purchase common stock in connection with the Business Combination | — | — | — | — | (2,568) | — | (2,568) | ||||||||||
| Issuance of common stock upon closing the Business Combination, net of expenses | — | — | 4,316,808 | — | 957 | — | 957 | ||||||||||
| Contingent earnout liability recognized upon closing of the Business Combination | — | — | — | — | (28,927) | — | (28,927) | ||||||||||
| Assumption of preferred stock in connection with the Business Combination | 4,015,002 | — | — | — | 34,150 | — | 34,150 | ||||||||||
| Net loss | — | — | — | — | — | (59,363) | (59,363) | ||||||||||
| At December 31, 2023 | 4,015,002 | $— | 26,413,213 | $2 | $222,437 | $(249,504) | $(27,065) | ||||||||||
| Exercise of options | — | — | 180,778 | — | 76 | — | 76 | ||||||||||
| Stock-based compensation | — | — | — | — | 5,441 | — | 5,441 | ||||||||||
| Proceeds from sale of common stock | — | — | 2,542,262 | 1 | 15,474 | — | 15,475 | ||||||||||
| Record exchange warrants | — | — | — | — | 11,924 | — | 11,924 | ||||||||||
| Record issuance costs | — | — | — | — | (1,700) | — | (1,700) | ||||||||||
| Issuance of common stock for exchange warrants | — | — | 2,110,366 | — | — | — | — | ||||||||||
| Preferred stock conversion | (30,000) | — | 32,645 | — | — | — | — | ||||||||||
| Net loss | — | — | — | — | — | (30,045) | (30,045) | ||||||||||
| At December 31, 2024 | 3,985,002 | $— | 31,279,264 | $3 | $253,652 | $(279,549) | $(25,894) | ||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.